vs
Apellis Pharmaceuticals, Inc.（APLS）与Vita Coco Company, Inc.（COCO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Vita Coco Company, Inc.的1.1倍（$199.9M vs $179.8M），Vita Coco Company, Inc.净利率更高（17.0% vs -29.5%，领先46.4%），Vita Coco Company, Inc.同比增速更快（37.3% vs -5.9%），过去两年Vita Coco Company, Inc.的营收复合增速更高（11.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
唯他可可（Vita Coco）是美国知名饮料企业，主打椰子水产品，是全球椰子水及植物基饮品赛道的头部品牌。截至2016年业务已覆盖31个国家，属于共益企业，由All Market Inc.控股。
APLS vs COCO — 直观对比
营收规模更大
APLS
是对方的1.1倍
$179.8M
营收增速更快
COCO
高出43.2%
-5.9%
净利率更高
COCO
高出46.4%
-29.5%
两年增速更快
COCO
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $179.8M |
| 净利润 | $-59.0M | $30.5M |
| 毛利率 | — | 39.9% |
| 营业利润率 | -25.6% | 18.7% |
| 净利率 | -29.5% | 17.0% |
| 营收同比 | -5.9% | 37.3% |
| 净利润同比 | -62.2% | 61.4% |
| 每股收益（稀释后） | $-0.40 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCOCO
| Q1 26 | — | $179.8M | ||
| Q4 25 | $199.9M | $127.8M | ||
| Q3 25 | $458.6M | $182.3M | ||
| Q2 25 | $178.5M | $168.8M | ||
| Q1 25 | $166.8M | $130.9M | ||
| Q4 24 | $212.5M | $127.3M | ||
| Q3 24 | $196.8M | $132.9M | ||
| Q2 24 | $199.7M | $144.1M |
净利润APLSCOCO
| Q1 26 | — | $30.5M | ||
| Q4 25 | $-59.0M | $5.5M | ||
| Q3 25 | $215.7M | $24.0M | ||
| Q2 25 | $-42.2M | $22.9M | ||
| Q1 25 | $-92.2M | $18.9M | ||
| Q4 24 | $-36.4M | $3.4M | ||
| Q3 24 | $-57.4M | $19.3M | ||
| Q2 24 | $-37.7M | $19.1M |
毛利率APLSCOCO
| Q1 26 | — | 39.9% | ||
| Q4 25 | — | 34.9% | ||
| Q3 25 | — | 37.7% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 36.7% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | — | 38.8% | ||
| Q2 24 | — | 40.8% |
营业利润率APLSCOCO
| Q1 26 | — | 18.7% | ||
| Q4 25 | -25.6% | 8.0% | ||
| Q3 25 | 48.7% | 15.3% | ||
| Q2 25 | -18.6% | 14.9% | ||
| Q1 25 | -50.0% | 14.7% | ||
| Q4 24 | -12.3% | 3.4% | ||
| Q3 24 | -24.0% | 15.5% | ||
| Q2 24 | -14.7% | 20.8% |
净利率APLSCOCO
| Q1 26 | — | 17.0% | ||
| Q4 25 | -29.5% | 4.3% | ||
| Q3 25 | 47.0% | 13.2% | ||
| Q2 25 | -23.6% | 13.6% | ||
| Q1 25 | -55.3% | 14.4% | ||
| Q4 24 | -17.1% | 2.6% | ||
| Q3 24 | -29.2% | 14.5% | ||
| Q2 24 | -18.9% | 13.2% |
每股收益（稀释后）APLSCOCO
| Q1 26 | — | $0.50 | ||
| Q4 25 | $-0.40 | $0.10 | ||
| Q3 25 | $1.67 | $0.40 | ||
| Q2 25 | $-0.33 | $0.38 | ||
| Q1 25 | $-0.74 | $0.31 | ||
| Q4 24 | $-0.30 | $0.06 | ||
| Q3 24 | $-0.46 | $0.32 | ||
| Q2 24 | $-0.30 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $201.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $352.2M |
| 总资产 | $1.1B | $488.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCOCO
| Q1 26 | — | $201.9M | ||
| Q4 25 | $466.2M | $196.9M | ||
| Q3 25 | $479.2M | $203.7M | ||
| Q2 25 | $370.0M | $167.0M | ||
| Q1 25 | $358.4M | $153.6M | ||
| Q4 24 | $411.3M | $164.7M | ||
| Q3 24 | $396.9M | $156.7M | ||
| Q2 24 | $360.1M | $150.1M |
股东权益APLSCOCO
| Q1 26 | — | $352.2M | ||
| Q4 25 | $370.1M | $331.5M | ||
| Q3 25 | $401.2M | $323.7M | ||
| Q2 25 | $156.3M | $296.9M | ||
| Q1 25 | $164.2M | $277.9M | ||
| Q4 24 | $228.5M | $258.8M | ||
| Q3 24 | $237.1M | $252.1M | ||
| Q2 24 | $264.3M | $232.0M |
总资产APLSCOCO
| Q1 26 | — | $488.3M | ||
| Q4 25 | $1.1B | $461.2M | ||
| Q3 25 | $1.1B | $461.3M | ||
| Q2 25 | $821.4M | $421.1M | ||
| Q1 25 | $807.3M | $384.0M | ||
| Q4 24 | $885.1M | $362.4M | ||
| Q3 24 | $901.9M | $353.1M | ||
| Q2 24 | $904.5M | $323.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSCOCO
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $-3.9M | ||
| Q3 25 | $108.5M | $39.1M | ||
| Q2 25 | $4.4M | $21.8M | ||
| Q1 25 | $-53.4M | $-9.8M | ||
| Q4 24 | $19.4M | $6.9M | ||
| Q3 24 | $34.1M | $9.3M | ||
| Q2 24 | $-8.3M | $26.9M |
自由现金流APLSCOCO
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $-7.1M | ||
| Q3 25 | $108.3M | $35.6M | ||
| Q2 25 | $4.4M | $20.9M | ||
| Q1 25 | $-53.4M | $-10.4M | ||
| Q4 24 | $19.3M | $6.8M | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | $-8.4M | $26.6M |
自由现金流率APLSCOCO
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | -5.6% | ||
| Q3 25 | 23.6% | 19.6% | ||
| Q2 25 | 2.5% | 12.4% | ||
| Q1 25 | -32.0% | -7.9% | ||
| Q4 24 | 9.1% | 5.3% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | -4.2% | 18.5% |
资本支出强度APLSCOCO
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.2% |
现金转化率APLSCOCO
| Q1 26 | — | — | ||
| Q4 25 | — | -0.70× | ||
| Q3 25 | 0.50× | 1.63× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | -0.52× | ||
| Q4 24 | — | 2.05× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
